ALZHEIMER’S ASSOCIATION STATEMENT

VIVIMIND Supplement for “Protecting Memory Function”

Chicago (September 2008) — The Alzheimer’s Association does not support use of the dietary supplement VIVIMIND — by people with Alzheimer’s disease or other dementia, family members of people with dementia, people worried about getting Alzheimer’s, or the general public.

At this time, there is no statistically significant proof that VIVIMIND is an effective treatment for Alzheimer’s disease or any related disorder. A Phase III clinical trial of the compound for Alzheimer’s disease failed – it showed no statistically significant benefit versus placebo for people with Alzheimer’s.

In addition, there is no evidence of its claims to protect against memory loss, preserve the brain structures associated with memory and learning, or maintain mental skills and abilities in healthy individuals at any age.

Marketing such a product is not in the best interest of people with Alzheimer’s and their families, or the general public. It is misleading and exploits people who are worried and vulnerable.

Everyone wants better treatments for Alzheimer’s and dementia. However, proof of the value of all interventions – including medical treatments, lifestyle changes, and dietary supplements – must precede new products into the marketplace. This product does not have that proof.

For more information about treatments for Alzheimer’s disease, and maintaining brain health as we age, please visit www.alz.org

# # #